Physicians' Academy for Cardiovascular Education
Inflammation is receiving increasing attention for a potential role in residual CV risk. Follow recent insights into the importance of inflammation of CVD.
AHA 2018 Paul Ridker outlines how the new CIRT results add to our understanding of inflammation biology in relation to CV risk and how this directs future studies of inflammation.
AHA 2018 Low-dose methotrexate did not lower IL-1β, IL-6 and CRP levels, nor did it reduce atherosclerotic events in patients with stable CAD, suggesting that the IL-1β to IL-6 to CRP pathway is important for atheroprotection.
A retrospective study showed that a high percentage of patients undergoing PCI have persistent high residual inflammatory risk, which results in a higher one year rate of all-cause death and myocardial infarction.
A retrospective study showed better SBP during antihypertensive therapy and lower risk of antihypertensive treatment failure in hypertensive patients with good oral health, as compared with those with periodontitis.
ESC 2018 Biomarkers play an important role in CV risk prediction. Nina Paynter, PhD, presents the definition of a good biomarker and explains how deep learning can improve CV risk assessment.
Prof. Jorge Plutzky explains BET inhibition as a novel therapeutic strategy for controlling pathologic cardiovascular responses.
In patients with an established diagnosis of hypercholesterolemia, tocilizumab blunted the NSTEMI-associated PCSK9 increase and this was strongly correlated with a decrease in neutrophil numbers.
In the REGARDS cohort, low hs-CRP levels were associated with a reduced risk of stroke, and CHD morbidity and mortality, while low LDL-c was not associated with protective effects.
ESC 2018 Cilie van 't Klooster asks Prof. Ridker how the results on canakinumab from the CANTOS trial can be implemented in clinical practice and which challenges are left?
Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CVD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.
A subanalysis of the CANTOS study showed that modulation of the IL-6 signaling pathway with IL-1β inhibitor canakinumab, associates with reduced CV event rates, independent of lipid lowering.
The testosterone/estradiol ratio reflects both systemic and plaque inflammation in men undergoing carotid endarterectomy. Low ratio was associated with higher MACE risk, especially in overweight men.
